SCHEMBL23817201

SCHEMBL23817201

C[C@@H](O)[C@@H](F)CN(C)C(=O)OC(C)(C)C

nearest known ligand 0.32

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CA14 Q9ULX7 1/20 0.32
HDAC6 Q9UBN7 2/20 0.32
APLNR P35414 1/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC2 Q92769 1/20 0.32
CACNA1G O43497 1/20 0.32
CACNA1B Q00975 1/20 0.32
CACNA1C Q13936 1/20 0.32
CTSK P43235 2/20 0.31
HTR2C P28335 1/20 0.30
SLC6A4 P31645 1/20 0.30
CYP2D6 P10635 1/20 0.30
CA1 P00915 1/20 0.30
CA2 P00918 1/20 0.30
CA7 P43166 1/20 0.30
PDK2 Q15119 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24904226 1.00 CA14 (0.32) CA14HDAC6APLNRHDAC1HDAC2
SCHEMBL13779828 0.83 CYP2D6 (0.33) CA14HDAC6APLNRHDAC1HDAC2
SCHEMBL23134818 0.82 MAPK1 (0.35) CA14HDAC6HDAC1HDAC2CACNA1G
SCHEMBL20215933 0.82 MAPK1 (0.35) CA14HDAC6HDAC1HDAC2CACNA1G
SCHEMBL22916149 0.81 CA14 (0.33) CA14HDAC6APLNRHDAC1HDAC2
SCHEMBL21610053 0.80 HDAC6 (0.34) CA14HDAC6HDAC1HDAC2CACNA1G
SCHEMBL21610067 0.80 HDAC6 (0.34) CA14HDAC6HDAC1HDAC2CACNA1G
SCHEMBL7601771 0.80 CA14 (0.36) CA14HDAC6APLNRHDAC1HDAC2
SCHEMBL1447140 0.80 HDAC6 (0.36) CA14HDAC6HDAC1HDAC2CACNA1G
SCHEMBL13490197 0.80 HDAC6 (0.36) CA14HDAC6HDAC1HDAC2CACNA1G

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023134266-A1 2-PIPERIDYL OR 2-PYRAZOLYL SUBSTITUTED PYRIMIDINE COMPOUND SERVING AS EGFR INHIBITOR 苏州浦合医药科技有限公司 2023-07-20 WO disclosed
WO-2021179274-A1 ErbB RECEPTOR INHIBITORS AS ANTI-TUMOR AGENTS SUZHOU ZANRONG PHARMA LTD. (CN) 2021-09-16 WO disclosed